Research on biomarker-driven therapy and immune check-point blockade in non-small cell
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …

KRAS G12C mutation (mKRAS G12C) is the most frequent KRAS point mutation in non-
small cell lung cancer (NSCLC) and has been proven to be a predictive biomarker for direct …

Simple Summary RAS mutation is the most frequent oncogenic alteration in human cancers
and KRAS is the most frequently mutated, notably in non-small cell lung carcinomas …

Background Real-world data on demographics related to KRAS mutation subtypes are
crucial as targeted drugs against the p. G12C variant have been approved. Method We …

Background The low level of circulating tumor DNA (ctDNA) in the blood is a well-known
challenge for the application of liquid biopsies in early-stage non-small cell lung cancer …

Introduction The frequency of actionable mutations varies between races, and
Hispanic/Latino (H/L) people are a population with different proportions of ancestry. Our …

Introduction With the approval of G12C inhibitors as the second line of treatment for KRAS
G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to …

Lung malignant tumors are a type of cancer with high incidence and mortality rates
worldwide. Non-small cell lung cancer (NSCLC) accounts for over 80% of all lung malignant …

Tropomyosin receptor kinases (TRK) are attractive targets for cancer therapy. As TRK-
inhibitors are approved for all solid cancers with detectable fusions involving the …

Background: KRAS mutation status is a well-established independent prognostic factor in
advanced non-small cell lung cancer (NSCLC), yet its role in early-stage disease is unclear …